Molecular Mechanisms and Therapies of Colorectal Cancer
Colorectal cancer (CRC) is currently the third leading cause of cancer-related mortality, with 1.9 million incidence cases and 0.9 million deaths worldwide. The global number of new CRC cases is predicted to reach 3.2 million in 2040, based on the projection of aging, population growth, and human de...
Gorde:
| Formatua: | Online |
|---|---|
| Hizkuntza: | ingelesa |
| Argitaratua: |
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| Gaiak: | |
| Sarrera elektronikoa: | ONIX_20230202_9783036565477_136 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
| _version_ | 1869523589274796032 |
|---|---|
| collection | Directory of Open Access Books |
| description | Colorectal cancer (CRC) is currently the third leading cause of cancer-related mortality, with 1.9 million incidence cases and 0.9 million deaths worldwide. The global number of new CRC cases is predicted to reach 3.2 million in 2040, based on the projection of aging, population growth, and human development.In clinics, despite advances of diagnosis and surgical procedures, 20% of the patients with CRC present with metastasis at the time of diagnosis, caused by residual tumor cells that have spread to distant organs prior to surgery, affecting the patient survival rate. Standard systemic chemotherapy, alternative therapies that target mechanisms involved in cancer progression and metastasis, immunotherapy, and combination therapies are the major CRC-treatment strategies. In the advanced stage of CRC the transforming growth factor-beta (TGF-β) plays an oncogenic role by promoting cancer cell proliferation, cancer cell self-renewal, epithelial-to-mesenchymal transition, invasion, tumor progression, metastatic spread, and immune escape. Furthermore, high levels of TGF-β1 confers poor prognosis and is associated with early recurrence after surgery, resistance to chemo- or immunotherapy, and shorter survival. Based on the body of experimental evidence indicating that TGF-β signaling has the potential to be a good therapeutic target in CRC, several anti-TGF-β drugs have been investigated in cancer clinical trials. Here, we presented a comprehensive collection of manuscripts regarding studies on targeting the TGF-β signaling in CRC to improve patient’s prognosis and personalized treatments. |
| format | Online |
| id | doab-20.500.12854ir-96735 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2023 |
| publishDateRange | 2023 |
| publishDateSort | 2023 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-967352024-03-31T13:10:42Z Molecular Mechanisms and Therapies of Colorectal Cancer Cave, Donatella Delle Ottaiano, Alessandro colorectal cancer miRNA ceRNA lncRNA circRNA sponging noninvasive biomarkers MiR-199b tumor suppressor prognosis LARC HOX HOXB9 colorectal liver metastases metastatic colorectal cancer structural variants common fragile sites platinum therapy stalled replication fork surgical oncology liver regeneration immunology hepatic tissue-resident memory T cells liver neoplasms neoplasm metastasis proteomics biomarkers mass spectrometry microRNA hypoxia hypoxia-regulated microRNAs fatty acid synthase lipid metabolism colorectal cancer initiation Apc mutation epigenetics methylation biomarker S-Adenosylmethionine breast cancer Notch metastasis EMT targeted sequencing inflammatory bowel diseases colitis-associated cancer phosphatidylinositol 3-kinase sortilin neurotensin neurotensin receptor-3 soluble sortilin cell signaling cell morphology colorectal carcinoma early onset CRC multi-omics lymphovascular invasion perineural invasion DNA damage repair DNA replication repair MMR base excision repair FASN CTLA4 HAVCR2 TGF-β signaling targeting therapy immune-suppressive barrier properties colon heterogeneity cytokines tumor necrosis factor alpha interleukin 10 tight junction proteins 1,2-dimethylhydrazine rat epithelial-to-mesenchymal transition tumor-associated macrophages thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology Colorectal cancer (CRC) is currently the third leading cause of cancer-related mortality, with 1.9 million incidence cases and 0.9 million deaths worldwide. The global number of new CRC cases is predicted to reach 3.2 million in 2040, based on the projection of aging, population growth, and human development.In clinics, despite advances of diagnosis and surgical procedures, 20% of the patients with CRC present with metastasis at the time of diagnosis, caused by residual tumor cells that have spread to distant organs prior to surgery, affecting the patient survival rate. Standard systemic chemotherapy, alternative therapies that target mechanisms involved in cancer progression and metastasis, immunotherapy, and combination therapies are the major CRC-treatment strategies. In the advanced stage of CRC the transforming growth factor-beta (TGF-β) plays an oncogenic role by promoting cancer cell proliferation, cancer cell self-renewal, epithelial-to-mesenchymal transition, invasion, tumor progression, metastatic spread, and immune escape. Furthermore, high levels of TGF-β1 confers poor prognosis and is associated with early recurrence after surgery, resistance to chemo- or immunotherapy, and shorter survival. Based on the body of experimental evidence indicating that TGF-β signaling has the potential to be a good therapeutic target in CRC, several anti-TGF-β drugs have been investigated in cancer clinical trials. Here, we presented a comprehensive collection of manuscripts regarding studies on targeting the TGF-β signaling in CRC to improve patient’s prognosis and personalized treatments. 2023-02-02T16:45:25Z 2023-02-02T16:45:25Z 2023 book ONIX_20230202_9783036565477_136 9783036565477 9783036565460 https://directory.doabooks.org/handle/20.500.12854/96735 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/6681 https://mdpi.com/books/pdfview/book/6681 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-6546-0 10.3390/books978-3-0365-6546-0 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036565477 9783036565460 294 Basel open access |
| spellingShingle | colorectal cancer miRNA ceRNA lncRNA circRNA sponging noninvasive biomarkers MiR-199b tumor suppressor prognosis LARC HOX HOXB9 colorectal liver metastases metastatic colorectal cancer structural variants common fragile sites platinum therapy stalled replication fork surgical oncology liver regeneration immunology hepatic tissue-resident memory T cells liver neoplasms neoplasm metastasis proteomics biomarkers mass spectrometry microRNA hypoxia hypoxia-regulated microRNAs fatty acid synthase lipid metabolism colorectal cancer initiation Apc mutation epigenetics methylation biomarker S-Adenosylmethionine breast cancer Notch metastasis EMT targeted sequencing inflammatory bowel diseases colitis-associated cancer phosphatidylinositol 3-kinase sortilin neurotensin neurotensin receptor-3 soluble sortilin cell signaling cell morphology colorectal carcinoma early onset CRC multi-omics lymphovascular invasion perineural invasion DNA damage repair DNA replication repair MMR base excision repair FASN CTLA4 HAVCR2 TGF-β signaling targeting therapy immune-suppressive barrier properties colon heterogeneity cytokines tumor necrosis factor alpha interleukin 10 tight junction proteins 1,2-dimethylhydrazine rat epithelial-to-mesenchymal transition tumor-associated macrophages thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology Molecular Mechanisms and Therapies of Colorectal Cancer |
| title | Molecular Mechanisms and Therapies of Colorectal Cancer |
| title_full | Molecular Mechanisms and Therapies of Colorectal Cancer |
| title_fullStr | Molecular Mechanisms and Therapies of Colorectal Cancer |
| title_full_unstemmed | Molecular Mechanisms and Therapies of Colorectal Cancer |
| title_short | Molecular Mechanisms and Therapies of Colorectal Cancer |
| title_sort | molecular mechanisms and therapies of colorectal cancer |
| topic | colorectal cancer miRNA ceRNA lncRNA circRNA sponging noninvasive biomarkers MiR-199b tumor suppressor prognosis LARC HOX HOXB9 colorectal liver metastases metastatic colorectal cancer structural variants common fragile sites platinum therapy stalled replication fork surgical oncology liver regeneration immunology hepatic tissue-resident memory T cells liver neoplasms neoplasm metastasis proteomics biomarkers mass spectrometry microRNA hypoxia hypoxia-regulated microRNAs fatty acid synthase lipid metabolism colorectal cancer initiation Apc mutation epigenetics methylation biomarker S-Adenosylmethionine breast cancer Notch metastasis EMT targeted sequencing inflammatory bowel diseases colitis-associated cancer phosphatidylinositol 3-kinase sortilin neurotensin neurotensin receptor-3 soluble sortilin cell signaling cell morphology colorectal carcinoma early onset CRC multi-omics lymphovascular invasion perineural invasion DNA damage repair DNA replication repair MMR base excision repair FASN CTLA4 HAVCR2 TGF-β signaling targeting therapy immune-suppressive barrier properties colon heterogeneity cytokines tumor necrosis factor alpha interleukin 10 tight junction proteins 1,2-dimethylhydrazine rat epithelial-to-mesenchymal transition tumor-associated macrophages thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology |
| topic_facet | colorectal cancer miRNA ceRNA lncRNA circRNA sponging noninvasive biomarkers MiR-199b tumor suppressor prognosis LARC HOX HOXB9 colorectal liver metastases metastatic colorectal cancer structural variants common fragile sites platinum therapy stalled replication fork surgical oncology liver regeneration immunology hepatic tissue-resident memory T cells liver neoplasms neoplasm metastasis proteomics biomarkers mass spectrometry microRNA hypoxia hypoxia-regulated microRNAs fatty acid synthase lipid metabolism colorectal cancer initiation Apc mutation epigenetics methylation biomarker S-Adenosylmethionine breast cancer Notch metastasis EMT targeted sequencing inflammatory bowel diseases colitis-associated cancer phosphatidylinositol 3-kinase sortilin neurotensin neurotensin receptor-3 soluble sortilin cell signaling cell morphology colorectal carcinoma early onset CRC multi-omics lymphovascular invasion perineural invasion DNA damage repair DNA replication repair MMR base excision repair FASN CTLA4 HAVCR2 TGF-β signaling targeting therapy immune-suppressive barrier properties colon heterogeneity cytokines tumor necrosis factor alpha interleukin 10 tight junction proteins 1,2-dimethylhydrazine rat epithelial-to-mesenchymal transition tumor-associated macrophages thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology |
| url | ONIX_20230202_9783036565477_136 |